Identification of Cooperative Gene Regulation Among Transcription Factors, LncRNAs, and MicroRNAs in Diabetic Nephropathy Progression

Overview

Journal Front Genet

Date 2020 Oct 22

PMID 33088282

Citations 6

Authors

Ling Chen

Binbin Wu

Shaobin Wang

Yu Xiong

Boya Zhou

Xianyi Cheng

Tao Zhou

Ruibang Luo

Tak-Wah Lam

Bin Yan

Junhui Chen

Affiliations

Soon will be listed here.

Abstract

The pathogenesis of diabetic nephropathy (DN) is accompanied by alterations in biological function and signaling pathways regulated through complex molecular mechanisms. A number of regulatory factors, including transcription factors (TFs) and non-coding RNAs (ncRNAs, including lncRNAs and miRNAs), have been implicated in DN; however, it is unclear how the interactions among these regulatory factors contribute to the development of DN pathogenesis. In this study, we developed a network-based analysis to decipher interplays between TFs and ncRNAs regulating progression of DN by combining omics data with regulatory factor-target information. To accomplish this, we identified differential expression programs of mRNAs and miRNAs during early DN (EDN) and established DN. We then uncovered putative interactive connections among miRNA-mRNA, lncRNA-miRNA, and lncRNA-mRNA implicated in transcriptional control. This led to the identification of two lncRNAs (MALAT1 and NEAT1) and the three TFs (NF-κB, NFE2L2, and PPARG) that likely cooperate with a set of miRNAs to modulate EDN and DN target genes. The results highlight how crosstalk among TFs, lncRNAs, and miRNAs regulate the expression of genes both transcriptionally and post-transcriptionally, and our findings provide new insights into the molecular basis and pathogenesis of progressive DN.

Citing Articles

MiR-192-5p targets cell cycle regulation in diabetic kidney disease via cyclin-dependent kinase inhibitor 3.

Sahoo B, Mishra D, Tiwari S Noncoding RNA Res. 2024; 11:60-72.

PMID: 39736853 PMC: 11683246. DOI: 10.1016/j.ncrna.2024.11.003.

Genome-wide analysis of long noncoding RNAs as cis-acting regulators of transcription factor-encoding genes in IgA nephropathy.

Zhai Y, Tian H, Zhang W, Sun S, Zhao Z PLoS One. 2024; 19(5):e0304301.

PMID: 38787831 PMC: 11125480. DOI: 10.1371/journal.pone.0304301.

Long non‑coding RNA L13Rik promotes high glucose-induced mesangial cell hypertrophy and matrix protein expression by regulating miR-2861/CDKN1B axis.

Sun L, Ding M, Chen F, Zhu D, Xie X PeerJ. 2023; 11:e16170.

PMID: 37868060 PMC: 10586299. DOI: 10.7717/peerj.16170.

LncRNA NEAT1 and MALAT1 are involved in polycystic ovary syndrome pathogenesis by functioning as competing endogenous RNAs to control the expression of PCOS-related target genes.

ElMonier A, El-Boghdady N, Fahim S, Sabry D, Elsetohy K, Shaheen A Noncoding RNA Res. 2023; 8(2):263-271.

PMID: 36935861 PMC: 10020466. DOI: 10.1016/j.ncrna.2023.02.008.

Using network pharmacology to explore the mechanism of Danggui-Shaoyao-San in the treatment of diabetic kidney disease.

Yang J, Li C, Liu Y, Han Y, Zhao H, Luo S Front Pharmacol. 2022; 13:832299.

PMID: 36059953 PMC: 9437281. DOI: 10.3389/fphar.2022.832299.

References

Yi J, Liu D, Xiao J . LncRNA MALAT1 sponges miR-30 to promote osteoblast differentiation of adipose-derived mesenchymal stem cells by promotion of Runx2 expression. Cell Tissue Res. 2018; 376(1):113-121. DOI: 10.1007/s00441-018-2963-2. View

Cardenas-Gonzalez M, Srivastava A, Pavkovic M, Bijol V, Rennke H, Stillman I . Identification, Confirmation, and Replication of Novel Urinary MicroRNA Biomarkers in Lupus Nephritis and Diabetic Nephropathy. Clin Chem. 2017; 63(9):1515-1526. PMC: 5610914. DOI: 10.1373/clinchem.2017.274175. View

Sankrityayan H, Kulkarni Y, Gaikwad A . Diabetic nephropathy: The regulatory interplay between epigenetics and microRNAs. Pharmacol Res. 2019; 141:574-585. DOI: 10.1016/j.phrs.2019.01.043. View

Guo J, Liu Z, Gong R . Long noncoding RNA: an emerging player in diabetes and diabetic kidney disease. Clin Sci (Lond). 2019; 133(12):1321-1339. DOI: 10.1042/CS20190372. View

Paraskevopoulou M, Georgakilas G, Kostoulas N, Reczko M, Maragkakis M, Dalamagas T . DIANA-LncBase: experimentally verified and computationally predicted microRNA targets on long non-coding RNAs. Nucleic Acids Res. 2012; 41(Database issue):D239-45. PMC: 3531175. DOI: 10.1093/nar/gks1246. View

Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi P . A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?. Cell. 2011; 146(3):353-8. PMC: 3235919. DOI: 10.1016/j.cell.2011.07.014. View

Kato M, Natarajan R . Diabetic nephropathy--emerging epigenetic mechanisms. Nat Rev Nephrol. 2014; 10(9):517-30. PMC: 6089507. DOI: 10.1038/nrneph.2014.116. View

Suryavanshi S, Kulkarni Y . NF-κβ: A Potential Target in the Management of Vascular Complications of Diabetes. Front Pharmacol. 2017; 8:798. PMC: 5681994. DOI: 10.3389/fphar.2017.00798. View

Bernardi S, Voltan R, Rimondi E, Melloni E, Milani D, Cervellati C . TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets?. Clin Sci (Lond). 2019; 133(10):1145-1166. PMC: 6526163. DOI: 10.1042/CS20181116. View

10.

Tay Y, Rinn J, Pandolfi P . The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014; 505(7483):344-52. PMC: 4113481. DOI: 10.1038/nature12986. View

11.

Duan L, Ding M, Hou L, Cui Y, Li C, Yu D . Long noncoding RNA TUG1 alleviates extracellular matrix accumulation via mediating microRNA-377 targeting of PPARγ in diabetic nephropathy. Biochem Biophys Res Commun. 2017; 484(3):598-604. DOI: 10.1016/j.bbrc.2017.01.145. View

12.

Bjornstad P, Cherney D, Maahs D . Early diabetic nephropathy in type 1 diabetes: new insights. Curr Opin Endocrinol Diabetes Obes. 2014; 21(4):279-86. PMC: 4138314. DOI: 10.1097/MED.0000000000000074. View

13.

Warren A, Knudsen S, Cooper M . Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies. Expert Opin Ther Targets. 2019; 23(7):579-591. DOI: 10.1080/14728222.2019.1624721. View

14.

Wu L, Wang Q, Guo F, Ma X, Ji H, Liu F . MicroRNA-27a Induces Mesangial Cell Injury by Targeting of PPARγ, and its In Vivo Knockdown Prevents Progression of Diabetic Nephropathy. Sci Rep. 2016; 6:26072. PMC: 4869109. DOI: 10.1038/srep26072. View

15.

Liu F, Tai Y, Ma J . LncRNA NEAT1/let-7a-5p axis regulates the cisplatin resistance in nasopharyngeal carcinoma by targeting Rsf-1 and modulating the Ras-MAPK pathway. Cancer Biol Ther. 2018; 19(6):534-542. PMC: 5927658. DOI: 10.1080/15384047.2018.1450119. View

16.

Huang B, Guo X, Li Y . lncRNA MALAT1 regulates the expression level of miR-21 and interferes with the biological behavior of colon cancer cells. J BUON. 2020; 25(2):907-913. View

17.

Li M, Sham P, Wang J . FastPval: a fast and memory efficient program to calculate very low P-values from empirical distribution. Bioinformatics. 2010; 26(22):2897-9. PMC: 2971576. DOI: 10.1093/bioinformatics/btq540. View

18.

Kato M . Noncoding RNAs as therapeutic targets in early stage diabetic kidney disease. Kidney Res Clin Pract. 2018; 37(3):197-209. PMC: 6147183. DOI: 10.23876/j.krcp.2018.37.3.197. View

19.

Navarro-Gonzalez J, Mora-Fernandez C, de Fuentes M, Garcia-Perez J . Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2011; 7(6):327-40. DOI: 10.1038/nrneph.2011.51. View

20.

Li J, Liu S, Zhou H, Qu L, Yang J . starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2013; 42(Database issue):D92-7. PMC: 3964941. DOI: 10.1093/nar/gkt1248. View